ICAP Grand Rounds Webinar- Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls
Two recent landmark HIV Prevention Trials Network (HPTN) studies demonstrated the efficacy of long-acting, injectable cabotegravir (CAB) as PrEP against HIV. These studies showed that CAB for PrEP injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for PrEP among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies demonstrated that CAB for PrEP was well-tolerated, offering a new and important PrEP option for individuals at risk for HIV infection.
As regulatory approvals for CAB for PrEP move forward, Raphael J. Landovitz, MD, MSc, the HPTN 03 Protocol chair, will discuss findings from the randomized controlled trial and ongoing open-label extension phases of the studies, including some thoughts on opportunities and challenges of clinical implementation in this grand rounds.
This webinar is being presented by ICAP. Based at Columbia University with operations in more than 30 countries, ICAP is a leader in global public health, internationally known for tackling the world’s toughest health challenges—from HIV to tuberculosis, from malaria to maternal and child health, and the growing problem of non-communicable diseases, and most recently, the COVID-19 pandemic. Through innovative research, collaborative technical assistance, and a focus on strengthening health systems, ICAP helps to create better, more accessible, health services to reduce the burden of illness on people and communities.
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in High-Income Countries
This article from Clinical Infectious Diseases examines potential barriers to scale-up of injectable PrEP in high income countries.
Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents
This article from Clinical Infectious Diseases examines the potential of injectable PrEP for HIV prevention in infants, children, and adolescents.
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries
This article from Clinical Infectious Diseases examines potential barriers to scale-up of injectable PrEP in low and middle income countries.
A Qualitative Exploration of New and Existing HIV PrEP Modalities Among Men Who Have Sex with Men in Philadelphia
This article from Open Forum Infectious Diseases explores the treatment characteristics that may influence the willingness and uptake of long-acting injectable PrEP as opposed to the daily pills among a racially diverse sample of gay and bisexual men who have sex with men in Philadelphia, Pennsylvania, USA.
Transgender Women in HPTN 083: An evaluation of safety, efficacy, and gender affirming hormonal therapy interactions with long-acting cabotegravir
This poster from AIDS 2022 presents an analysis of results from the HPTN 083 study, looking at the impact of feminizing gender affirming hormones on cabotegravir (CAB) for PrEP pharmacokinetics.
Relative Cost-effectiveness of Long-acting Injectable Cabotegravir versus Oral Pre-exposure Prophylaxis in South Africa based on the HPTN 083 and HPTN 084 Trials: A modelled economic evaluation and threshold analysis
This article from The Lancet HIV estimates the incremental cost-effectiveness of long-acting injectable cabotegravir (CAB for PrEP) compared with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC oral PrEP) in South Africa, using methods standard to government planning, and determines the threshold price at which CAB for PrEP is as cost-effective as TDF/FTC oral PrEP.
Acceptability of Injectable Pre-exposure Prophylaxis among People who Inject Drugs in Three Urban U.S. Settings
This article from BMC Infectious Diseases examines acceptability of injectable PrEP amongst people who inject drugs in the US.
Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?
This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.
Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models
This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.